Shanghai Healthcare Capital
VC Fund
Shanghai Healthcare Capital is a VC fund focused on Health Care and Biotechnology. Shanghai Healthcare Capital
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Shanghai Healthcare Capital invests in
Stages Shanghai Healthcare Capital invests in
Countries Shanghai Healthcare Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Liu
|
|||
Investment Focus
Industry
- Health Care 7 (58%)
- Biotechnology 6 (50%)
- Therapeutics 5 (42%)
- Medical 4 (33%)
- Pharmaceutical 3 (25%)
Stage
- Series B 4 (33%)
- Series A 3 (25%)
- Series D 3 (25%)
- Seed 1 (8%)
- Venture - Series Unknown 1 (8%)
Country
- China 8 (67%)
- United States 2 (17%)
- Israel 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Liu
Partner
|
Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VelaVigo
|
VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $60M / Seed / Jul 28, 2025 | |
Brattea
|
Brattea is a medical device research and development company. Brattea focuses on the development and commercialization of renal denervation products with indications in hypertension, cancer pain and diabetes. | Series D / Mar 25, 2024 | |
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $5M / Series A / Sep 27, 2023 | |
Next Generation Gene Therapeutics
|
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world.NGGT was founded in March 2020by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products. | $40M / Series B / Jul 11, 2023 | |
ReLive Biotechnologies LTD
|
ReLive is a biotechnology company that develops orthopedic sports medicine and plastic and reconstructive surgery projects based on regenerative medicine and cell therapy science. | $43M / Series A / Jan 16, 2023 | |
ArriVent
|
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. | $155M / Series B / Dec 29, 2022 | |
Biomica
|
Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI-related disorders. | $20M / Venture - Series Unknown / Dec 21, 2022 | |
Ranok Therapeutics
|
Ranok is a privately held, pre clinical stage bio company that is pioneering an innovative targeted protein degradation technology. | $40M / Series B / Aug 19, 2021 | |
Abbisko Therapeutics
|
Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China. | $123M / Series D / Jan 07, 2021 | |
Immvira
|
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. | Series B / Sep 24, 2020 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shanghai Healthcare Capital invest in?
Shanghai Healthcare Capital invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shanghai Healthcare Capital?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shanghai Healthcare Capital?
The team at Shanghai Healthcare Capital includes David Liu (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
